Syndax Pharmaceuticals, Inc. (SNDX) SEC Filings & Earnings Calls

Indebtedness and convertible note risk

“Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations and impair our ability to satisfy our obligations under our indebtedness.” · word for word

Dependence on key products

“We currently have two commercially approved medicines, Revuforj and Niktimvo, and a robust pipeline of late- and early-stage development programs.” · word for word

Clinical trial uncertainty

“Clinical development timelines, the probability of success and development costs can differ materially from expectations.” · word for word

Dependence on two key products for revenue; pipeline assets are early stage

“both our medicines now annualizing at well over $200 million each” · word for word

Clinical trial risks for pipeline assets; topline data expected in 4Q26

“Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD” · word for word

Potential shareholder dilution from convertible notes.

“a maximum of 13,631,400 shares of Common Stock may be issued upon conversion”

Potential dilution from new equity incentive plan and ESPP.

“reservation of 7,200,000 shares”

Potential shareholder dilution from convertible notes.

“The conversion rate for the Notes will initially be 40.3894 shares of Common Stock per $1,000 principal amount”

Accumulated deficit and ongoing losses

“As of March 31, 2026, we had an accumulated deficit of $1.5 billion.” · word for word

Dependence on two approved products

“We currently have two commercially approved medicines, Revuforj and Niktimvo.” · word for word

Royalty interest expense from Royalty Pharma agreement

“Royalty interest expense increased due to the interest expense recognized related to the Royalty Pharma Purchase and Sale Agreement signed in November 2024.” · word for word

Dependence on two products

“We currently have two commercially approved medicines, Revuforj and Niktimvo.” · word for word

Accumulated deficit

“As of December 31, 2025, we had an accumulated deficit of $1.5 billion.” · word for word

Royalty Pharma obligation

“Aggregate payments to Royalty Pharma pursuant to the Royalty Agreement are capped at $822.5 million or 2.35 times the funded amount.” · word for word

Dependence on two products; pipeline milestones subject to clinical and regulatory risk.

“Revenue concentrated in Revuforj and Niktimvo; Phase 2 IPF trial topline data expected 4Q26.”

Preliminary financials subject to adjustment; reliance on two recently launched products.

“The preliminary fourth quarter and full year 2025 financial results are preliminary, unaudited, subject to adjustment.” · word for word

Boxed warning for differentiation syndrome and QTc prolongation

“The Revuforj U.S. Prescribing Information label contains a boxed warning for differentiation syndrome, which can be fatal, as well as QTc prolongation and Torsades de Pointes.” · word for word

Competition from approved cGVHD drugs

“For example, cGVHD has historically been managed by off-label treatments. However, in the past several years, the FDA has approved three drugs, ibrutinib ( Imbruvica ® ), belomosidil ( Rezurock ® ) and ruxolitinib ( Jakafi ® ), for use in patients with cGVHD after failure of one or more lines of systemic therapy.” · word for word

Government shutdown risk

“If the current government shutdown continues or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business” · word for word

Dependence on two key products for revenue; pipeline execution risk for future growth.

“Revenue concentrated in Revuforj and Niktimvo; pipeline trials in early stages.”

Commercial execution risk for newly approved drug; forward-looking statements caution about uncertainties.

“This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company’s plans to make Revuforj commercially available.” · word for word